Palmitoylethanolamide (PEA) powder (544-31-0)

Palmitoylethanolamide (PEA) powder is an endogenous fatty acid amide. It is a weak ligand of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors. Palmitoylethanolamide acts by binding to an unidentified cannabinoid receptor that is similar to CB2, exhibits anti-inflammatory, anti-nociceptive, neuroprotective, and anticonvulsant properties in vivo. Producing robust anti-inflammatory actions by activating PPARα, acts as a selective agonist for GPR55 receptors (EC50 = 4, 19 800 and > 30 000 nM at GPR55, CB2 and CB1 receptors respectively).

Manufacture:  Batch Production
Package:  1KG/bag, 25KG/drum
Wisepowder has the capability to produce and supply large quantity. All production under cGMP condition and strict quality control system, all testing documents and sample available.

Palmitoylethanolamide (PEA) powder video


Palmitoylethanolamide (PEA) powder (544-31-0) Base Information

Name Palmitoylethanolamide (PEA) powder
CAS 544-31-0
Purity oil solubility, water solubility, fine powder, general powder
Chemical name Palmitoylethanolamide


Synonyms Palmidrol;Impulsin;544-31-0;N-palmitoylethanolamine;Palmitinsaeure-beta-hydroxyethylamid;(Hydroxyethyl)palmitamide; 2-(Palmitoylamino)ethanol; 2-Palmitamidoethanol; AM 3112; Loramine P 256; Mackpeart DR 14V;  N-(2-Hydroxyethyl)palmitamide; N-Hexadecanoylethanolamine; NSC 23320; Palmitic Acid Monoethanolamide; Palmitic Monoethanolamide
Molecular Formula C18H37NO2
Molecular Weight 299.49
Melting Point 97-98° C
Form A crystalline solid
Appearance White to Off-White powder
Half Life 0.292 Days (12-hr day; 1.5E6 OH/cm3)
Solubility Soluble in DMSO (20 mM), ethanol (25 mM), chloroform, THF ( at 30° C), and DMF (~10 mg/ml).
Storage Condition Store in a cool and dry place, get away from direct sun
Application Palmitoylethanolamide is an endogenous CB2 cannabinoid receptor agonist and selective GPR55 agonist
Testing Document Available


Palmitoylethanolamide (PEA) powder (544-31-0) powder General Description

Palmitoylethanolamide powder is an endogenous cannabinoid found in brain, liver, and other mammalian tissues. It is a weak ligand of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors, it has been found to inhibits fatty acid amide hydrolase (FAAH) ((IC50 = 5.1 μM).  Modulates mast cell activation. Palmitoylethanolamide powder exhibits anti-nociceptive, anti-inflammatory, anti-convulsant and immunosuppresant activity. It is a N-(long-chain-acyl)ethanolamine, an endocannabinoid and a N-(saturated fatty acyl)ethanolamine. It derives from a hexadecanoic acid. Palmitoylethanolamide powder acts by binding to an unidentified cannabinoid receptor that is similar to CB2. It also acts as a selective activator of the GPR55 receptor.

Palmitoylethanolamide powder, (also called palmitoylethanolamine or N-2 hydroxyethyl palmitamide), is one of the most important endogenous painkilling and anti-inflammatory compounds and has been shown to effective for both acute and chronic pain.Because the substance acts as a natural painkiller, it is an excellent alternative for conventional medications that might cause side effects.

Palmitoylethanolamide powder has been used for many decades in the Netherlands and Europe, but since the 1990s interest in the U.S. has surged. It is classified as a “food for medical purposes” in Europe and as a diet supplement in the U.S.


Palmitoylethanolamide (PEA) powder History

Palmitoylethanolamide (PEA) powder, the naturally occurring amide of ethanolamine and palmitic acid, is an endogenous lipid that modulates pain and inflammation. Interest in the anti-inflammatory properties of palmitoylethanolamide powder was first noted in the early 1950’s by Coburn et al. (1954) who found that feeding guinea pigs a diet high in egg yolk protected them from experimental allergy. Subsequent studies isolated and purified palmitoylethanolamide powder from egg yolk and identified the anti-inflammatory properties in animals. Research interest in NAE’s was revived in the 1990’s following the discovery of another endogenous NAE, AEA, with similar properties to the active component of cannabis. The cloning of the cannabinoid receptors (designated CBi and CB2) and the generation of selective CB receptor ligands provided the tools to further accelerate research activity. Since then a substantial body of evidence gathered from animal and human studies has shown that palmitoylethanolamide powder has anti-inflammatory and analgesic properties when given via different routes of administration.


Palmitoylethanolamide (PEA) Mechanism Of Action

Palmitoylethanolamide powder activates the energy-boosting, fat-burning, and anti-inflammatory PPAR alpha. By activating this key protein, Palmitoylethanolamide powder stops the activity of pro-inflammatory genes and the production of many inflammatory substances.

Palmitoylethanolamide powder reduces the activity of the bliss gene FAAH that breaks down natural cannabinoid anandamide. This increases the levels of calming anandamide in your body, helping to combat pain and increase relaxation. It may also activate cannabinoid receptors (CB2 and CB1).

Palmitoylethanolamide powder contains the palmitic acid in its structure. The starting point for making Palmitoylethanolamide powder in the body is precisely this saturated fatty acid.

However, simply increasing your intake of palmitic acid or other dietary fats will not affect Palmitoylethanolamide powder production in the body. This is because your body will use Palmitoylethanolamide powder only when it needs to compensate for inflammation or pain, and its levels will also normally vary throughout the day. The best way to get the benefits of Palmitoylethanolamide powder are standardized supplements, or alternatively Palmitoylethanolamide powder-rich foods.


Palmitoylethanolamide (PEA) Application

Palmitoylethanolamide (PEA) Powder is an endogenous fatty acid amide, an analog of the endocannabinoid anandamide (AEA), that belongs to the family of N-acylethanolamines (NAE). NAEs are released from cells in response to noxious stimuli. As all NAEs, also the Palmitoylethanolamide (PEA) Powder has a local effect, and its tissue levels are closely regulated through the balance of production and degradation activity. Two intracellular amidases, expressed in the inflammatory cells, have been involved in lipid amide degradation: fatty-acid amide hydrolase (FAAH) and N-acylethanolamine hydrolyzing acid amidase (NAAA). Palmitoylethanolamide (PEA) Powder has been demonstrated to bind to a receptor in the cell-nucleus (a nuclear receptor) and exerts a great variety of biological functions related to chronic pain and inflammation.


Palmitoylethanolamide (PEA) More research

Palmitoylethanolamide (PEA) Powder is a natural substance produced by the body and found in various foods. It is not an opioid. It is not addictive. Preliminary studies indicate that Palmitoylethanolamide (PEA) Powder does not develop pharmacological tolerance or gradually lose effectiveness over time as occurs with opioids. It has been shown to be safe for patients with no reported serious side effects and it is considered to lack acute or chronic toxicity. It does not interfere with other medication therapies nor does it trigger drug-drug interactions. There are no known contraindications for Palmitoylethanolamide (PEA) Powder, and patients with reduced kidney and liver function can be treated with Palmitoylethanolamide (PEA) Powder, as its metabolism  is localized and cellular and independent of kidney and liver functions. As with many medications, the safety with long term use over 60 days has not been well studied although thete are reports in the literature of long term use with no problems identified.


Palmitoylethanolamide (PEA) Reference

  • [1]Cruccu G, Di Stefano G, Marchettini P, Truini A.CNS Neurol Disord Drug Targets. 2019 Jul 3. doi: 10.2174/1871527318666190703110036. PMID: 31269891
  • [2]Noli C, Della Valle MF, Miolo A, Medori C, Schievano C; Skinalia Clinical Research Group.Vet Dermatol. 2019 Jun 24. doi: 10.1111/vde.12764. PMID: 31237065
  • [3]Contarini G, Franceschini D, Facci L, Barbierato M, Giusti P, Zusso M.J Neuroinflammation. 2019 Jun 20;16(1):126. doi: 10.1186/s12974-019-1514-4. PMID: 31221190
  • [4]Boccella S, Marabese I, Iannotta M, Belardo C, Neugebauer V, Mazzitelli M, Pieretti G, Maione S, Palazzo E. Int J Mol Sci. 2019 Apr 9;20(7). pii: E1757. doi: 10.3390/ijms20071757. PMID: 30970677
  • Does Palmitoylethanolamide(PEA) Have Weight Loss Benefits?


Trending Articles